SCHEMBL10068167

SCHEMBL10068167

CCC(O)COC(=O)NC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.44
EPHX1 P07099 1/20 0.44
CHRNB2 P17787 2/20 0.41
CHRNA4 P43681 2/20 0.41
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM5 P08912 1/20 0.41
CYP2D6 P10635 1/20 0.41
CHRM1 P11229 1/20 0.41
NFKB1 P19838 1/20 0.41
CHRM3 P20309 1/20 0.41
MAPK1 P28482 1/20 0.41
CHRNA7 P36544 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 2/20 0.39
APEX1 P27695 1/20 0.39
KDM4E B2RXH2 1/20 0.34
DUSP3 P51452 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13347915 0.89 CHRNB2 (0.45) CYP1A2EPHX1CHRNB2CHRNA4CHRM2
SCHEMBL140355 0.83 LMNA (0.46) CYP1A2EPHX1CHRNB2CHRNA4CHRM2
SCHEMBL27558053 0.83 LMNA (0.46) CYP1A2EPHX1CHRNB2CHRNA4CHRM2
SCHEMBL21344297 0.83 LMNA (0.46) CYP1A2EPHX1CHRNB2CHRNA4CHRM2
SCHEMBL21098353 0.81 CHRNB2 (0.44) CYP1A2EPHX1CHRNB2CHRNA4CHRM2
SCHEMBL10068346 0.81 SMN1; SMN2 (0.54) EPHX1CHRNB2CHRNA4SMN1; SMN2KDM4E
SCHEMBL19853430 0.81 CHRNB2 (0.44) CYP1A2EPHX1CHRNB2CHRNA4CHRM2
SCHEMBL12999571 0.81 SMN1; SMN2 (0.42) CHRNB2CHRNA4SMN1; SMN2LMNAKDM4E
SCHEMBL20075983 0.80 EPHX1 (0.45) CYP1A2EPHX1CHRNB2CHRNA4CHRM2
SCHEMBL13662404 0.78 CYP1A2 (0.47) CYP1A2EPHX1CHRNB2CHRNA4CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3609888-A1 FARNESOID X RECEPTOR AGONISTS AND USES THEREOF Metacrine, Inc. (US) 2020-02-19 EP claimed
WO-2018170182-A1 FARNESOID X RECEPTOR AGONISTS AND USES THEREOF METACRINE, INC. (US) 2018-09-20 WO claimed
US-11236071-B1 Farnesoid X receptor agonists and uses thereof METACRINE, INC. (US) 2022-02-01 US disclosed
US-8097741-B2 Hybrid coatings prepared from glycidyl carbamate resins NDSU RESEARCH FOUNDATION (US) 2012-01-17 US disclosed
US-20110288230-A1 METHOD FOR PREPARING POLYHYDROXY-URETHANES RHODIA OPERATIONS (FR) 2011-11-24 US disclosed
US-20110288230-A1 METHOD FOR PREPARING POLYHYDROXY-URETHANES RHODIA OPERATIONS (FR) 2011-11-24 US disclosed
US-8017719-B2 Method for preparing polyhydroxy-urethanes RHODIA OPERATIONS (FR) 2011-09-13 US disclosed
US-8017719-B2 Method for preparing polyhydroxy-urethanes RHODIA OPERATIONS (FR) 2011-09-13 US disclosed
US-7846638-B2 Composition for forming anti-reflective coating for use in lithography NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-12-07 US disclosed
US-20090312502-A1 Method for preparing polyhydroxy-urethanes RHODIA OPERATIONS (FR) 2009-12-17 US disclosed
US-20090312502-A1 Method for preparing polyhydroxy-urethanes RHODIA OPERATIONS (FR) 2009-12-17 US disclosed
US-7425399-B2 Composition for forming anti-reflective coating for use in lithography NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-09-16 US disclosed
WO-2008107568-A2 METHOD FOR PREPARING POLYHYDROXY-URETHANES RHODIA OPERATIONS (FR) 2008-09-12 WO disclosed
US-20080206680-A1 Composition for forming anti-reflective coating for use in lithography NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11236071-B1 Farnesoid X receptor agonists and uses thereof NR1H4, NR1H2, NR1H3 CYP1A2 494/4885EPHX1 369/4885CHRNB2 1769/4885
US-20110288230-A1 METHOD FOR PREPARING POLYHYDROXY-URETHANES UROD, HPD, ALKBH3 CYP1A2 421/4885EPHX1 999/4885CHRNB2 4550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.